English Version Schlieren, Switzerland, Munich, Germany, and Vienna, Austria, December 16, 2022 Clemedi AG concludes a license agreement for detecting latent tuberculosis with the Max Planck Society (MPG) and the Medical University of Vienna Clemedi aims to extend its tuberculosis product line to cover latent tuberculosis. This requires the ability to extract M. tuberculosis DNA…
read more Clemedi AG releases Tuberculini, its first molecular test for drug-resistant tuberculosis. Tuberculini is optimized to run on Thermo Fisher Scientific’s Ion GeneStudio S5™ System. Clemedi has developed a next-generation sequencing (NGS) based test called Tuberculini, that can recognise resistance to all major therapeutic agents used to treat tuberculosis. The assay – which received a CE-IVD…
read more